The conference will be held at the Grecotel Kos Imperial, Kos, Greece on May 26 - 31, 2021.

Organizing committee:
Belinda Parker, Leonidas Platanias, Mathias Müller and Serge Y Fuchs.

The Conference is under the sponsorship of Aegean Conferences, a non-profit educational organization promoting science through focused scientific conferences (www.aegeanconferences.org). Registration will be limited to 80-110 participants for this meeting; therefore, there should be ample opportunities for interactions and discussions.

Please click this link (http://www.aegeanconferences.org/src/App/conferences/view/150) to go to the Aegean Conferences 4th International Conference on Cytokines in Cancer meeting website for further info.

Klara Klein from the Institute of Pharmacology and Toxicology at the Vetmeduni in Vienna received the DOC grant from the Austrian Academy of Sciences to develop her project "Oncogenic mechanisms of mutant STAT5B in natural killer cells" over the next two years.

With the funding program "DOC", the Austrian Academy of Sciences (ÖAW) supports highly qualified PhD students from different research areas. From July 1st 2020, Klara Klein will receive the "DOC Scholarship" (in the sum of 38,000€) for her promising PhD project which addresses whether and how a mutation of the transcription factor STAT5B contributes to the malignant transformation of natural killer cells (NK). In the course of the project, supervised by Veronika Sexl, a novel mouse model will be developed that allows the STAT5B mutation to be restricted to NK cells. This will potentially clarify whether mutated STAT5B leads directly to the development of NK cell leukemia or lymphoma and whether the mutation of the transcription factor STAT5B represents a potential target for new therapies.

On November 27th 2019, Science was celebrated as part of the Science Day at Vetmeduni Vienna with a keynote by Nuno Maulide (UniVienna), awards for outstanding scientific work, the kick-off of the entrepreneurial Vetmed initiative and networking among researchers.

Rectorate of Vetmeduni Vienna honors employees and their scientific performance scientists by awarding internal science prizes for “invention of the year”, “most cited scientist”, “highest third-party funding” and the "major project of the year" with internal science prizes. The prizes were awarded according to the different career stage, in clinical and non-clinical categories, as well as in two age groups (younger than 35 years and older than 35 years). Of note, Richard Moriggle and Heidi Neubauer, from the Department of Functional Cancer Genomics, won Prizes for “most cited scientist” in the non-clinical category. Pictures of the event can be found here.

We are pleased to announce the second Cold Spring Harbor winter 2020 conference on JAK-STAT Pathways in Health & Disease, which will begin at 7:30 pm on Monday, April 6 and run through lunch on Thursday, April 9. 

Topics:

  • Jak-STAT Mutations and Genomic Functions
  • JAK-STAT Signaling in the Hematopoietic System
  • STAT3, Metabolism and Cancer
  • JAK-STAT Signaling and Regulation
  • Transcriptional and Epigenetic Regulation by STATs
  • JAK-STAT Inhibition

https://meetings.cshl.edu/meetings.aspx?meet=stats&year=20

cold spring harbor labratory

Iris Uras Jodl, from the Institute of Pharmacology and Toxicology at Vetmeduni Vienna, was awarded the Wilhelm Türk Prize of the Austrian Society for Hematology & Medical Oncology for the best scientific work in the field of hematology. The award ceremony took place on October 12th 2019 as part of the joint annual conference of the German, Austrian and Swiss societies for hematology and medical oncology, in Berlin.

The Wilhelm Türk Prize is primarily intended to promote young scientists and is awarded once a year for outstanding research work in the field of hematology. The award is endowed with € 5,000. This year Iris Uras was able to convince the reviewers with her article "Cdk6 coordinates Jak2 V617F mutant MPN via NFkB and apoptotic networks" published in journal Blood, under the supervision of Veronika Sexl. Uras Jodl researched the role of Cyclin-dependent kinase 6 (CDK6) in the development of myeloproliferative neoplasia (MPN) using mouse models.

The symposium will be held at the Vetmeduni Vienna on October 18, 2019. The symposium invited three international renown speakers who work in basic and translational biomedical sciences. The symposium is organized and supported by SFB F61 JakStat Monarchies.

 

 

Veronika Sexl, Head of the Institute for Pharmacology and Toxicology at Vetmeduni Vienna, and Florian Grebien, Head of the Institute for Medical Biochemistry at Vetmeduni Vienna, are working on survival rates of leukemia patients. They are financially supported by the European Research Council (ERC). They have talked about teamwork, crazy concepts and their intersections with veterinary medicine in the VETMED conversation.

The protein CDK6 is at the centre of Veronika Sexl's scientific work at the Institute of Pharmacology and Toxicology. "Starting with this tiny molecule, we're doing broad research," explains the scientist. It has long been known that CDK6 plays a role in many cancers because it drives cell division. It is particularly present in higher amounts in the case of leukemia. "This is why many cancer researchers are working on targeting this protein in the cells by developing special inhibitors against CDK6", says Veronika Sexl. "For the first time we were able to show that CDK6 can and does much more than previously thought."

With the same general goal, but with a different research approach, Florian Grebien is also interested in developing new treatments for cancer. His focus is on the molecular mechanisms behind the development of leukemia. “Our focus is on the so-called fusion proteins”, says Florian Grebien. “They arise when chromosomes break and are incorrectly reassembled. Cancer is very often driven by these fusion proteins. If you study them functionally, you can learn a lot about what processes a cell needs to become a cancer cell”.

Both researchers and their projects are currently funded by European Research Council (ERC) grants. In 2016 Sexl received an “Advanced Grant” worth 2.5 million euros. Florian Grebien was awarded a “Starting Grant” worth 1.5 million euros in 2015.

The full interview can be found here.

As part of the 3rd International Conference on Cytokine Signaling in Cancer in Rhodes, Greece, the Travel Awards were again awarded this year. Two of the awards went to Sebastian Kollmann from the Institute of Pharmacology and Toxicology and Anna Orlova from the Department of Functional Cancer Genomics at Vetmeduni Vienna.

In the project "STAT5A and STAT5B in Hematopoietic and Leukemic Stem Cells - Between Death and Immortality", Sebastian Kollmann addresses the question of why mutations in lymphoma and leukemia patients are mainly found in STAT5B and hardly in the related protein STAT5A. It describes an important role for STAT5B in the self-renewal of hematopoietic and leukemic stem cells and thereby contributes with basic information to understand this question.

In the study “The ERBB-STAT3 Axis Drives Tasmanian Devil Facial Tumor Disease”, Anna Orlova shows that the overactivation of ERBB receptors, and consequently also of STAT3, leads to the transferability of facial tumours among Tasmanian devils. The study also unravels that the cancer cells can be specifically targeted by drug inhibition of the ERBB receptor.

Tobias Suske is a PhD student in the group of Richard Moriggl at the Institute of Animal Breeding and Genetics, Vetmeduni Vienna. He was honored with the Young Investigator Award at the Annual Meeting of the OeGHO & AHOP in Linz AT for his excellent talk on “The gain-of-function STAT5BN642H mutation as a driver of T-cell lymphoma and leukemia”.

The Austrian Society for Haematology and Clinical Oncology (OeGHO, www.oegho.at) and the Working Group for Haematological and Oncological Nursing (AHOP, www.ahop.at) have been awarding outstanding research of young investigators since 2010. The award is € 1.000 and is donated by Janssen Cilag Pharma GmbH.


©OeGHO


©OeGHO

Tobias Suske, PhD student at the Institute for Animal Breeding and Genetics at Vetmeduni Vienna, was awarded at the Annual Meeting of the Austrian Society for Hematology and Medical Oncology (OeGHO) and the Working Group for Hematological and Oncological Nurses (AHOP) spring conference 2019 for his outstanding presentation “The gain-of-function STAT5BN642H mutation as a driver of T-cell lymphoma and leukemia”. With his work, he won the Young Investigator Award.

Tobias Suske from the Functional Cancer Genomics Department at the Institute of Animal Breeding and Genetics received one of the young talent awards. The Young Investigator Awards are endowed with 1000€ each and are awarded by Janssen Cilag Pharma GmbH. In his PhD project, Tobias Suske studied the STAT5BN642H mutation. This genetic change has been found frequently in recent years in patients with T-cell lymphomas and leukemias, who are usually extremely aggressive and difficult to treat. The research focuses on understanding the mutation at the molecular level in order to create therapeutic approaches for targeted active substances.